Biotech RadarJobs updated

COMPANY

Nurix Therapeutics

HQ: Brisbane, CA source · nurixtx.com ↗ · West Coast

Clinical Phase 3

43 open jobs · last seen Oct 23, 2026 · 13 sources

Keywords: oncology neurology immunology Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Diffuse Large B Cell Lymphoma B-cell Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Waldenstrom Macroglobulinemia Primary Central Nervous System Lymphoma Cervical Cancer Secondary Central Nervous System Lymphoma Epithelial Ovarian Cancer Gastric Cancer GastroEsophageal Junction (GEJ) Cancer Head and Neck Squamous Cell Carcinoma Metastatic or Unresectable Melanoma Non-small Cell Lung Cancer Metastatic Castration-resistant Prostate Cancer Malignant Pleural Mesothelioma Triple Negative Breast Cancer Metastatic Urothelial Carcinoma Richter Transformation Microsatellite Stable Colorectal Carcinoma Platinum-resistant Ovarian Cancer Endometrial Cancer NX-5948 NX-2127 NX-1607 Drug Product De-TIL-0255

Profile checked Oct 10, 2026

Since the raise (Oct 27, 2025): 43 of 43 open jobs were first seen after it.

43Open jobs$250.0MRaised (2 yrs)10Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Director, Quality AssuranceBrisbane, CaliforniaOct 22, 2026Oct 23, 2026
Senior/Principal Scientist, Medicinal ChemistryThe Woodlands, TexasOct 22, 2026Oct 23, 2026
Scientist I, BioanalyticalBrisbane, CaliforniaOct 21, 2026Oct 22, 2026
Senior Research Associate, Preclinical PharmacologyBrisbane, CaliforniaOct 14, 2026Oct 14, 2026
Senior Scientist, Medicinal ChemistryThe Woodlands, TexasOct 13, 2026Oct 14, 2026

See all 43 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Board tracked Radar started tracking this company’s job board (43 open jobs at last check). source ↗
  2. Trial start Phase 3: Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL source ↗
  3. Trial start Phase 1/Phase 2: Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies source ↗
  4. Partnership Partnership / licensing: $700M (upfront, as published); deal value up to $2.3B (kept separate from upfront), announced Jun 7, 2026. Source: SEC filing. source ↗
  5. Raise Follow-on offering: $250M (total, as published), announced Oct 27, 2025. Source: company release on GlobeNewswire. source ↗
  6. Trial start Phase 2: A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) source ↗
  7. Trial start Phase 1: A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers source ↗
  8. Trial start Phase 1: Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948 source ↗
  9. Trial start Phase 1: A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects source ↗
  10. Trial start Phase 1: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies source ↗
  11. Trial start Phase 1: A Study of DeTIL-0255 in Adults With Advanced Malignancies source ↗
  12. Trial start Phase 1: A Study of NX-1607 in Adults With Advanced Malignancies source ↗
  13. Trial start Phase 1: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 43

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Director, Quality AssuranceBrisbane, CaliforniaOct 22, 2026Oct 23, 2026Not stated
Senior/Principal Scientist, Medicinal ChemistryThe Woodlands, TexasOct 22, 2026Oct 23, 2026Not stated
Scientist I, BioanalyticalBrisbane, CaliforniaOct 21, 2026Oct 22, 2026Not stated
Senior Research Associate, Preclinical PharmacologyBrisbane, CaliforniaOct 14, 2026Oct 14, 2026Senior
Senior Scientist, Medicinal ChemistryThe Woodlands, TexasOct 13, 2026Oct 14, 2026Senior
Scientist I, Medicinal ChemistryThe Woodlands, TexasOct 12, 2026Oct 13, 2026Entry
Senior Director, Head of Pharmacovigilance OperationsBrisbane, CaliforniaOct 8, 2026Oct 9, 2026Executive
Senior Manager / Associate Director, Regulatory Affairs CMC (Small Molecules)Brisbane, CaliforniaOct 8, 2026Oct 9, 2026Senior
Administrative Assistant, Clinical Development (Contract)Brisbane, CaliforniaOct 5, 2026Oct 9, 2026Entry
Administrative Assistant, CMC (Contract)Brisbane, CaliforniaOct 5, 2026Oct 9, 2026Entry
Principal Engineer, Pharmaceutical DevelopmentBrisbane, CaliforniaOct 5, 2026Oct 9, 2026Senior
Associate Director, Regulatory & Medical WritingBrisbane, CaliforniaSep 27, 2026Oct 9, 2026Senior
Director, Drug SafetyBrisbane, CaliforniaSep 27, 2026Oct 9, 2026Senior
Talent Acquisition Analyst - ContractBrisbane, CaliforniaSep 24, 2026Oct 9, 2026Mid
Recruiting Coordinator (Contract)Brisbane, CaliforniaSep 24, 2026Oct 9, 2026Entry
Senior Clinical Trial Manager (Sr. CTM)Brisbane, CaliforniaSep 24, 2026Oct 9, 2026Senior
Senior Clinical Trial Associate (Sr. CTA)Brisbane, CaliforniaSep 24, 2026Oct 9, 2026Senior
Clinical Trial Manager (CTM)Brisbane, CaliforniaSep 24, 2026Oct 9, 2026Mid
Executive Business PartnerBrisbane, CaliforniaSep 22, 2026Oct 9, 2026Senior
Senior Director, Translational Medicine and Clinical BiomarkersBrisbane, CaliforniaSep 20, 2026Oct 9, 2026Senior
Director, Total RewardsBrisbane, CaliforniaSep 20, 2026Oct 9, 2026Senior
Senior Manager / Associate Director, Publications and Medical Information (Contract)Brisbane, CaliforniaSep 18, 2026Oct 9, 2026Senior
Senior Manager, electronic Quality Management System (eQMS)Brisbane, CaliforniaSep 9, 2026Oct 9, 2026Senior
Director, Nonclinical Toxicology OperationsBrisbane, California, United StatesSep 8, 2026Oct 9, 2026Senior
Senior Manager/Associate Director, Regulatory Affairs (Strategy, Hematology Oncology)Brisbane, California, United StatesSep 7, 2026Oct 9, 2026Senior
Senior Director, Quality ControlBrisbane, California, United StatesSep 6, 2026Oct 9, 2026Senior
Associate Director, Chemical EngineeringBrisbane, California, United StatesSep 6, 2026Oct 9, 2026Senior
Senior Analyst, FP&ABrisbane, California, United StatesSep 3, 2026Oct 9, 2026Senior
Medical Director / Senior Medical DirectorBrisbane, California, United StatesSep 3, 2026Oct 9, 2026Senior
Medical Director / Senior Medical DirectorBrisbane, California, United StatesSep 3, 2026Oct 9, 2026Senior
Medical Director / Senior Medical Director 5948-306Brisbane, California, United StatesSep 2, 2026Oct 9, 2026Senior
Vice President / Senior Vice President, Global Development LeaderBrisbane, California, United StatesAug 28, 2026Oct 9, 2026Executive
Senior Scientist, Analytical Development and Quality Control - Early PhaseBrisbane, CA Aug 25, 2026Oct 9, 2026Senior
Executive Assistant to the CHRO - Contract to PermBrisbane, California, United StatesAug 22, 2026Oct 9, 2026Senior
Senior Manager, External Quality-Supply ChainBrisbane, CaliforniaAug 14, 2026Oct 9, 2026Senior
Scientist I, Bioanalytical – Drug Antibody Conjugates (DACs)Brisbane, CaliforniaAug 5, 2026Oct 9, 2026Entry
Director / Sr. Director, Regulatory Affairs (Strategy, Oncology Solid Tumors)Brisbane, CaliforniaAug 2, 2026Oct 9, 2026Senior
Director, IT Infrastructure & OperationsBrisbane, CAJul 15, 2026Oct 9, 2026Senior
Director, Pharmaceutical DevelopmentBrisbane, CAJul 10, 2026Oct 9, 2026Senior
Vice President, Medical Affairs – Hematology-OncologyBrisbane, CA Jun 8, 2026Oct 9, 2026Executive
Senior Research Associate, DNA Encoded Library Technology ~ ContractBrisbane, CA May 17, 2026Oct 9, 2026Senior
Senior Manager, Analytical Development and Quality Control - Drug ProductBrisbane, CA May 13, 2026Oct 9, 2026Senior
Director, Regulatory Affairs (Strategy, I&I)Brisbane, California, United StatesMay 4, 2026Oct 9, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $250.0M. Last 2 years.

Clinical trials (lead sponsor) 10

RecordTitlePhaseStatusStartPrimary completion
NCT07221500A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)Phase 2RecruitingOct 15, 20252028-01 (estimated)
NCT07516093Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLPhase 3RecruitingAug 3, 20262029-10 (estimated)
NCT07520006Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesPhase 1/Phase 2Recruiting2026-082033-05 (estimated)
NCT06717269A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy VolunteersPhase 1CompletedNov 30, 2024May 1, 2026 (actual)
NCT05131022A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesPhase 1RecruitingApr 13, 20222027-01 (estimated)
NCT04830137A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesPhase 1RecruitingMay 5, 20212026-05 (estimated)
NCT05107674A Study of NX-1607 in Adults With Advanced MalignanciesPhase 1RecruitingSep 29, 2021Aug 31, 2026 (estimated)
NCT06593457A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult SubjectsPhase 1CompletedAug 20, 2024Oct 29, 2024 (actual)
NCT06691828Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948Phase 1CompletedNov 1, 2024Nov 28, 2024 (actual)
NCT05107739A Study of DeTIL-0255 in Adults With Advanced MalignanciesPhase 1TerminatedDec 22, 2021May 9, 2023 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Nurix Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback